ASHMEDIUM SIGNALFINANCIAL10-K

Ashland shows broad-based financial contraction with revenue declining 13.7% alongside meaningful reductions in assets, equity, and capital investments.

The synchronized decline across revenue, assets, and stockholders' equity suggests either significant divestitures or operational challenges affecting the specialty chemicals company. The sharp reduction in share buybacks from $380M to $100M indicates management is preserving cash amid the financial contraction, which could signal either strategic repositioning or response to business headwinds.

Comparing 2025-11-20 vs 2024-11-18View on EDGAR →
FINANCIAL ANALYSIS

Ashland experienced a coordinated financial contraction with revenue declining 13.7% to $1.8B while total assets fell 18.3% to $4.6B and stockholders' equity dropped 33.6% to $1.9B. The company reduced capital expenditures by 28.5% and dramatically cut share buybacks by 73.7% to $100M, suggesting management is conserving cash. While gross profit margins held relatively steady despite the revenue decline, the broad-based nature of the financial reductions indicates either major asset divestitures or significant operational challenges facing the specialty additives company.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-73.7%
$380.0M→$100.0M

Buyback activity reduced 73.7% — capital being redeployed elsewhere or cash conservation underway.

Stockholders Equity
Balance Sheet
-33.6%
$2.9B→$1.9B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-28.5%
$137.0M→$98.0M

Capex reduced 28.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-28.3%
$300.0M→$215.0M

Cash decreased 28.3% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
-18.3%
$5.6B→$4.6B

Total assets contracted 18.3% — asset sales, write-downs, or balance sheet optimization underway.

SG&A Expense
P&L
-14.9%
$404.0M→$344.0M

SG&A reduced 14.9% — improved cost efficiency or headcount reduction improving operating margins.

Revenue
P&L
-13.7%
$2.1B→$1.8B

Revenue softened 13.7% — monitor whether this is cyclical or structural.

Current Liabilities
Balance Sheet
-13.7%
$490.0M→$423.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
-11.2%
$618.0M→$549.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2025-11-20
PRIOR — 2024-11-18
ADDED
As of October 31, 2025, there w ere 45,718,113 sha res of Common Stock outstanding.
is a global additives and specialty ingredients company with a conscious and proactive mindset for sustainability.
Our common stock is listed on the New York Stock Exchange ( NYSE ) under the ticker symbol ASH .
The terms Ashland, the Company, we and our used herein refer to Ashland Inc., a Delaware Corporation, and its predecessors, and its consolidated subsidiaries, except where the context indicates otherwise.
Ashland s reportable operating segments ("reportable segments") include: Life Sciences; Personal Care; Specialty Additives; and Intermediates.
+7 more — sign up free →
REMOVED
In determining this amount, the Registrant has assumed that its directors and executive officers are affiliates.
Such assumption shall not be deemed conclusive for any other purpose.
At October 31, 2024, there w ere 47,109,326 sha res of Registrant s common stock outstanding.
is a Delaware corporation, with its headquarters and principal executive offices at 8145 Blazer Drive, Wilmington, Delaware 19808.
Our common stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol ASH .
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →